123 related articles for article (PubMed ID: 31337591)
1. The differential effect of sub-micron level HA aggregates on influenza potency assays.
Lemieux M; Lorbetskie B; Luebbert CC; Walrond L; Li C; Li X; Cyr T; Sauvé S; Johnston MJW; Farnsworth A
Vaccine; 2019 Aug; 37(36):5276-5287. PubMed ID: 31337591
[TBL] [Abstract][Full Text] [Related]
2. An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines.
Bodle J; Vandenberg K; Laurie K; Barr IG; Zhang Y; Rockman S
Front Immunol; 2023; 14():1147028. PubMed ID: 37033922
[TBL] [Abstract][Full Text] [Related]
3. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.
Schmeisser F; Jing X; Joshi M; Vasudevan A; Soto J; Li X; Choudhary A; Baichoo N; Resnick J; Ye Z; McCormick W; Weir JP
Influenza Other Respir Viruses; 2016 Mar; 10(2):134-40. PubMed ID: 26616263
[TBL] [Abstract][Full Text] [Related]
4. Reference antigen-free and antibody-free LTD-IDMS assay for influenza H7N9 vaccine in vitro potency determination.
Morgenstern K; Xie Y; Palladino G; Barr JR; Settembre EC; Williams TL; Wen Y
Vaccine; 2018 Oct; 36(41):6144-6151. PubMed ID: 30194004
[TBL] [Abstract][Full Text] [Related]
5. Trypsin pre-treatment corrects SRID over-estimation of immunologically active, pre-fusion HA caused by mixed immunoprecipitin rings.
Wen Y; Palladino G; Xie Y; Ferrari A; Ma X; Han L; Dormitzer PR; Settembre EC
Vaccine; 2016 Jun; 34(29):3388-95. PubMed ID: 27154389
[TBL] [Abstract][Full Text] [Related]
6. Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity.
Wen Y; Palladino G; Xie Y; Ferrari A; Settembre EC
Vaccine; 2018 May; 36(21):3010-3017. PubMed ID: 29680201
[TBL] [Abstract][Full Text] [Related]
7. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies.
Verma S; Soto J; Vasudevan A; Schmeisser F; Alvarado-Facundo E; Wang W; Weiss CD; Weir JP
PLoS One; 2017; 12(4):e0175733. PubMed ID: 28423025
[TBL] [Abstract][Full Text] [Related]
8. A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines.
Schmeisser F; Vasudevan A; Soto J; Kumar A; Williams O; Weir JP
Influenza Other Respir Viruses; 2014 Sep; 8(5):587-95. PubMed ID: 25087462
[TBL] [Abstract][Full Text] [Related]
9. Potency determination of inactivated H7 influenza vaccines using monoclonal antibody-based ELISA and biolayer interferometry assays.
Vasudevan A; Woerner A; Schmeisser F; Verma S; Williams O; Weir JP
Influenza Other Respir Viruses; 2018 Mar; 12(2):250-258. PubMed ID: 29152878
[TBL] [Abstract][Full Text] [Related]
10. Conformationally selective biophysical assay for influenza vaccine potency determination.
Wen Y; Han L; Palladino G; Ferrari A; Xie Y; Carfi A; Dormitzer PR; Settembre EC
Vaccine; 2015 Oct; 33(41):5342-5349. PubMed ID: 26348403
[TBL] [Abstract][Full Text] [Related]
11. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.
Schmeisser F; Vodeiko GM; Lugovtsev VY; Stout RR; Weir JP
Vaccine; 2010 Mar; 28(12):2442-9. PubMed ID: 20074687
[TBL] [Abstract][Full Text] [Related]
12. Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay.
Chae W; Kim P; Hwang BJ; Seong BL
Vaccine; 2019 Mar; 37(11):1457-1466. PubMed ID: 30765169
[TBL] [Abstract][Full Text] [Related]
13. Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine.
Ekimov A; Arunachalam AB; Blake T; Bodle J; Couzens L; Dubey S; Eichelberger M; Engelhardt OG; Gubinelli F; Joshi M; Melnyk D; Palladino G; Rigsby P; Rockman S; Savina N; Smith E; Gilchrist SAN;
Vaccine; 2023 Jul; 41(32):4639-4647. PubMed ID: 37344260
[TBL] [Abstract][Full Text] [Related]
14. VaxArray for hemagglutinin and neuraminidase potency testing of influenza vaccines.
Kuck LR; Byrne-Nash R; Gillis J; Bueter K; Couzens LK; Eichelberger MC; Rowlen KL
Vaccine; 2018 May; 36(21):2937-2945. PubMed ID: 29699789
[TBL] [Abstract][Full Text] [Related]
15. Rapid determination of influenza vaccine potency by an SPR-based method using subtype or lineage-specific monoclonal antibodies.
Narayan K; Paduraru C; Blake T; Arunachalam AB
Front Immunol; 2023; 14():1128683. PubMed ID: 37457687
[TBL] [Abstract][Full Text] [Related]
16. Hemagglutinin Quantitative ELISA-based Potency Assay for Trivalent Seasonal Influenza Vaccine Using Group-Specific Universal Monoclonal Antibodies.
Chae W; Kim P; Kim H; Cheong YC; Kim YS; Kang SM; Seong BL
Sci Rep; 2019 Dec; 9(1):19675. PubMed ID: 31873147
[TBL] [Abstract][Full Text] [Related]
17.
An Y; Parsons LM; Jankowska E; Melnyk D; Joshi M; Cipollo JF
J Virol; 2019 Jan; 93(2):. PubMed ID: 30355697
[TBL] [Abstract][Full Text] [Related]
18. Plant-expressed HA as a seasonal influenza vaccine candidate.
Shoji Y; Chichester JA; Bi H; Musiychuk K; de la Rosa P; Goldschmidt L; Horsey A; Ugulava N; Palmer GA; Mett V; Yusibov V
Vaccine; 2008 Jun; 26(23):2930-4. PubMed ID: 18440103
[TBL] [Abstract][Full Text] [Related]
19. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China.
Li C; Shao M; Cui X; Song Y; Li J; Yuan L; Fang H; Liang Z; Cyr TD; Li F; Li X; Wang J
Biologicals; 2010 Mar; 38(2):284-9. PubMed ID: 20074976
[TBL] [Abstract][Full Text] [Related]
20. Immunocapture isotope dilution mass spectrometry in response to a pandemic influenza threat.
Pierce CL; Williams TL; Santana WI; Levine M; Chen LM; Cooper HC; Solano MI; Woolfitt AR; Marasco WA; Fang H; Donis RO; Barr JR
Vaccine; 2017 Sep; 35(37):5011-5018. PubMed ID: 28774565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
